Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue European Heart Journal - Cardiovascular Pharmacotherapy Année : 2019

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54

Deepak Bhatt
Andrezej Budaj
  • Fonction : Auteur
Christian Hamm
  • Fonction : Auteur
Jindrich Spinar
  • Fonction : Auteur
Robert Kiss
  • Fonction : Auteur
José Lopez-Sendon
  • Fonction : Auteur
Gabriel Kamensky
  • Fonction : Auteur
Diego Ardissino
  • Fonction : Auteur
Frederic Kontny
  • Fonction : Auteur
Per Johanson
  • Fonction : Auteur
Olof Bengtsson
  • Fonction : Auteur
Anders Himmelmann
  • Fonction : Auteur

Résumé

AIMS: In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier. We report the efficacy and safety in the subpopulation recommended for treatment in the European (EU) label, i.e. treatment with 60 mg b.i.d. initiated up to 2 years from the MI, or within 1 year after stopping previous adenosine diphosphate receptor inhibitor treatment. METHODS AND RESULTS: Of the 21 162 patients enrolled in PEGASUS-TIMI 54, 10 779 patients were included in the primary analysis for this study, randomized to ticagrelor 60 mg (n = 5388) or matching placebo (n = 5391). The cumulative proportions of patients with events at 36 months were calculated by the Kaplan-Meier (KM) method. The composite of CV death, MI, or stroke occurred less frequently in the ticagrelor group (7.9% KM rate vs. 9.6%), hazard ratio (HR) 0.80 [95% confidence interval (CI) 0.70-0.91; P = 0.001]. Ticagrelor also reduced the risk of all-cause mortality, HR 0.80 (0.67-0.96; P = 0.018). Thrombolysis in myocardial infarction major bleeding was more frequent in the ticagrelor group 2.5% vs. 1.1%; HR 2.36 (1.65-3.39; P < 0.001). The corresponding HR for fatal or intracranial bleeding was 1.17 (0.68-2.01; P = 0.58). CONCLUSION: In PEGASUS-TIMI 54, treatment with ticagrelor 60 mg as recommended in the EU label, was associated with a relative risk reduction of 20% in CV death, MI, or stroke. Thrombolysis in myocardial infarction major bleeding was increased, but fatal or intracranial bleeding was similar to placebo. There appears to be a favourable benefit-risk ratio for long-term ticagrelor 60 mg in this population.
Fichier principal
Vignette du fichier
pvz020.pdf (465.48 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-02341886 , version 1 (31-10-2019)

Identifiants

Citer

Mikael Dellborg, Marc P Bonaca, Robert Storey, P Gabriel Steg, Kyung A Im, et al.. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5 (4), pp.200-206. ⟨10.1093/ehjcvp/pvz020⟩. ⟨hal-02341886⟩
25 Consultations
46 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More